chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Left supraclavicular lymphadenopathy; This is a spontaneous report from a contactable consumer, the physician. A 61-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an intramuscular route of administration in the left arm on 25Apr2021 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history reported as the patient need to release the information. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included methylphenidate (MANUFACTURER UNKNOWN), venlafaxine (MANUFACTURER UNKNOWN) and rosuvastatin (MANUFACTURER UNKNOWN); all for unknown indication, from an unknown start date and unknown if on going. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 04May2021, the patient experienced left supraclavicular lymphadenopathy, no other lymphadenopathy was found and no other symptoms. The reporter tried to speak to someone at Pfizer to see if this particular side effect has occurred with this vaccine, but was unable to get a person on the telephone. If someone could call him, he told he would appreciate it and given his office contact number. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event left supraclavicular lymphadenopathy was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
This case was reported by a consumer (the company owner) and described the occurrence of injection site redness in a subject of unspecified age and gender who was vaccinated with FLULAVAL (GlaxoSmithKline). A physician or other health care professional has not verified this report. On an unspecified date the subject received a dose of FLULAVAL (details unknown). At an unspecified time after vaccination with FLULAVAL, the subject experienced injection site redness. At the time of reporting the outcome of the event was unspecified. The consumer reported that 5 employees at one company and one employee at another company all reported extreme redness at the injection site after receiving FLULAVAL. This is case 1 of 6 (see case IDs A0952653A-A0952657A for details of the other reports).
Headache onset around 20:00, nausea and vomiting starting at 21:30 and lasting 24 hours with diarrhea, body aches, and chills.  Unable to confirm fever.   Attempted resolve with Pepto Bismol and Tylenol, but was not able to keep it down.  Any fluid or food intake (Gatorade, pedialyte, ice chips, saltine crackers) were immediately thrown up.   About 21:00 on April 1, I was able to take and keep down a Tylenol PM and promethazine 12.5mg tablet.  Additional promethazine tablet taken on April 2 at 10:00 for residual nausea.  Slight soreness throughout body, no fever, no diarrhea, no chills at time of writing this description.
1 week after the shot, symptoms are worse with the pain in left arm & neck & back. Also have pain behind my left knee. Still experiencing radiating pain from the area where the shot was received. Been using heat/ice/tylonel.
Information has been received from an advance registered nurse practitioner concerning a male patient who on 03-MAR-2009 was vaccinated SQ with a 0.65 mL dose of ZOSTAVAX (Merck). About 3 weeks later the patient got shingles that "was not very bad". The nurse was not sure if the patient had a prior history of shingles but she said she would indicate this in follow-up because she did not have available the patient's chart. The patient called the office seeking medical attention. At the time of reporting the patient had not recovered. Additional information has been requested.
Numbness in her arms, hands, and fingers; Tingling in her arms, hands, and fingers; This case was reported by a physician via call center representative and described the occurrence of numbness of upper extremities in a adult female patient who received Herpes zoster (Shingrix) (batch number E4E39, expiry date 24th August 2023) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On an unknown date, 1 day after receiving Shingrix, the patient experienced numbness of upper extremities and tingling. On an unknown date, the outcome of the numbness of upper extremities and tingling were recovered/resolved.   It was unknown if the reporter considered the numbness of upper extremities and tingling to be related to Shingrix.     Additional Information: GSK receipt date :08July 2022 Reporters comment: The reporter consent for follow-up. The reporter IS physician he reported that the female patient received first dose of shingrix vaccine and experienced Tingling and numbness in arm hand and figure. Additional Supportive information:As per source document narrative mentioned ''the day after''as patient experienced event after the vaccination so TTO captured as 1 day
pain at injection site headache chills and overall muscle aches. several hours after getting shot I am better today but still have a headache and pain at injection site.
Milk supply dropped for over 3 weeks. Produced 20-25 once to 4-6 ounces
Given vaccination at work (home health nurse) started having chills. On 11/6/2009 woke up with Cold symptoms, overall pain, fatigue, low grade fever, sore throat.
This spontaneous report as received from a Licensed Vocational Nurse refers to a patient of unknown age and gender. Medical history and concurrent conditions were not provided. On an unknown date, the patient was vaccinated "early" with the third dose of GARDASIL 0.5 ml, intramuscularly (lot number and expiry date were not reported). The reporter was not sure whether the dose in question was GARDASIL or GARDASIL 9. There was no concomitant medication provided. Additional information has been requested.
A week later patient had 103 temperature (rectal) and was treated with Tylenol and Motrin at bedtime. On Wednesday patient developed large welt at ProQuad injection site. Grew longer and darker red as days progressed. On 3/3 went to doctor and had red spots all over body. Today they are even more around, 20 on face and legs and 30/40 on trunk.
At 2pm, while driving on freeway, patient could not breathe.  Patient got off the freeway and called 911; they intubated her on the spot.  Patient taken to Medical Center; and was hospitalized for 9 days--discharged on 10/26.  Patient diagnosis was anaphylaxis, acute respiratory failure, and Takotsubo cardiomyopathy (broken heart syndrome).  After discharge patient followed up with PCP (Dr.) and cardiologist (Dr.). Went into AFib, so had 2 visits to hospital (Hospital) both ER and hospital3 days. Patient had a cardio eco also. Patient was cardioverted twice in this facility. Patient had had several hospital visits to hospital. On 12/20 had a visit because of slight Pneumonia; patient was given prescription for antibiotics.  On 2/18 patient was cardioverted in same facility before going back. Before vaccine, patient had not had AFib for 2.5 years. AFib-wise, patient has been doing well since last procedure.  Patient has been in contact with PCP over the phone and has not been able to go to the cardiologist because of Coronavirus. Patient shakes all the time; never did that before vaccine. Patient has also lost a lot of weight since then.  Three years ago, patient had breathing problems when received the Flu vaccine; the adverse events were just slight so vaccine was not contraindicated.  Patient received Flu vaccine in 10/17 because deceased son had cancer and did not want to compromise him.
Pt recv vax on 1/4/99; on same day pt exp fever (103), irritable, vomiting, rash: red, raised on on face & torso; dx= febrile rash
Headache, Myalgia, ARM PAIN Narrative:  Other Relevant History:
Information has been received from a registered nurse concerning a female between the ages of 14 to 21 years old who was vaccinated IM into the deltoid region with a first 0.5 mL dose of HPV rL1 6 11 16 18 VLP vaccine (yeast). Subsequently, the patient experienced extreme pain during injection. The patient had to lie down for a short time period until the pain subsided. No medical attention was sought. About 15 to 20 minutes after injection, the patient was improving. No product quality complaint was involved. Additional information has been requested.
0.5 ML DOSE GIVEN AS 2 TIMES OF 0.25 ML DOSES AT THE SAME VISIT (OFF LABEL DOSING FREQUENCY); This spontaneous report received from a patient concerned a female of unspecified age, race and ethnicity. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient been covid free. The patient had previously received initial dose of covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: 204A21A and expiry: Unknown) 0.5 ml, 1 total, dose 1 administered on 28-APR-2021 for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with initial dose of covid-19 vaccine ad26.cov2.s (dose number in series 1). The patient received booster dose of covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin not reported, batch number: 1821286 and expiry: Unknown) 1 total, dose 2 administered on 29-OCT-2021, 0.5 ml dose given as 2 times of 0.25 ml doses at the same visit for covid-19 prophylaxis which was off label dosing frequency associated with off label use (dose number in series 2). No concomitant medications were reported. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of 0.5 ml dose given as 2 times of 0.25 ml doses at the same visit (off label dosing frequency) was not reported. This report was non-serious. This case, involving the same patient is linked to 20230138182. This case, from the same reporter is linked to 20230138443.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose 12/30/21,pfizer,Lot#EL0142 2nd dose: 01/20/21,Pfizer,Lot# EL3247 Diagnosed covid positive: Exposure:Home Symptoms:Cough,HA,Runny nose,loss of smell/taste,nasal congestion
This facility staff member received her first dose of the MODERNA COVID-19 vaccine (Lot037K20A/EXP 6/22/21) at clinic at approximately 9:15AM on 1/14/21. She initially answered "no" to any allergies on the VAR but revealed to the pharmacist reviewing the VAR that she had experienced an allergy to food and contrast dye that required an epi-pen and hospital attention. She did not offer additional details and explained that she had tolerated other shots (including the 2020 flu shot) without incident. I advised patient to remain for a 30 minute monitoring period post-vaccination due to history of allergic reaction. Patient presented with some anxiety before the shot and immediately started to complain of feeling "sick" and said she was having trouble breathing due to chest pressure. We advised patient to remove her mask and provided her with water and a trash can though no vomiting occurred. After 15-20 minutes, patient still complained of chest pressure and difficulty breathing. When asked if she was experiencing any itchiness or throat swelling, patient said she did feel some throat swelling so she was given 25MG of Benadryl. After an additional 15 minutes, patient's condition seemed unchanged (not worsening, not improving) so the facility's nursing team was called to evaluate patient. Patient said she was still experiencing difficulty breathing and throat swelling so nursing advised use of EPI-PEN and patient consented. I administered a dose of 0.3MG (LOT0FM4066/EXP 02/2022) to the right lateral thigh and nurse called for EMS. Immediately after injection, patient's eyes fluttered and she seemed to be on the verge of fainting. Nursing checked her oxygen saturation which was 100%. Patient reported no improvement after 5 minutes so another EPI-PEN 0.3MG was administered to the left lateral thigh. Nursing also gave the patient 81MG chewable aspirin due to the patient experiencing a stroke last month. EMS arrived a few minutes after the second EPI-PEN dose and patient was transported to the hospital for evaluation. Facility reported that patient went home that afternoon but did not provide details. Based on my assessment of patient's symptoms and behavior, I feel it is likely that she experienced either an acute panic attack or anaphylaxis due to vaccine administration. I called the patient today (the day after the incident) and she confirms that she received treatment for an anaphylactic reaction to the Moderna COVID shot and is doing well without any lasting adverse effects.
PATIENT WAS GIVEN 0.3 ML OF UNDILUTED PFIZER-BIONTECH COVID-19 VACCINE.  AS OF 2 HOURS AFTER ADMINISTERING THE VACCINE, SHE HAS HAD ZERO SIDE EFFECTS.
rapid heart rate; Bruise; Pain at the injection site; Fatigue; Nausea; Headache; This spontaneous case was reported by a physician and describes the occurrence of HEART RATE INCREASED (rapid heart rate), CONTUSION (Bruise), VACCINATION SITE PAIN (Pain at the injection site), FATIGUE (Fatigue) and NAUSEA (Nausea) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Dec-2020, the patient experienced HEART RATE INCREASED (rapid heart rate), CONTUSION (Bruise), VACCINATION SITE PAIN (Pain at the injection site), FATIGUE (Fatigue), NAUSEA (Nausea) and HEADACHE (Headache). On 29-Dec-2020, HEART RATE INCREASED (rapid heart rate) outcome was unknown. On 30-Dec-2020, VACCINATION SITE PAIN (Pain at the injection site), FATIGUE (Fatigue), NAUSEA (Nausea) and HEADACHE (Headache) outcome was unknown. At the time of the report, CONTUSION (Bruise) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.  No concomitant medication was provided.
SEVERE DIZZINESS IMMEDIATELY FOLLOWING VACCINATION; SHORTNESS OF BREATH, AND FEELING 'OUT OF IT' RESOLVED WITHOUT MEDICATIONS
Headache & Fever Narrative:  fever 102.7, chills, cold sores, aches
Redness, swelling at injection site the day after receiving vaccine. Tenderness to the touch for approx 3 days, followed by itchiness. Reporting issues 7 days after vaccination...injection site is swollen, fees heavy and itchy, feels firm to the touch (like a knot under the skin). Low grade fever (99.1 degrees F).
had to take days at work; got sick with high temperature; This spontaneous case was reported by a consumer and describes the occurrence of IMPAIRED WORK ABILITY (had to take days at work) and PYREXIA (got sick with high temperature) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 11-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced IMPAIRED WORK ABILITY (had to take days at work) and PYREXIA (got sick with high temperature). At the time of the report, IMPAIRED WORK ABILITY (had to take days at work) and PYREXIA (got sick with high temperature) outcome was unknown.            No concomitant medications reported.  Treatment information not reported.
Received menstrual symptoms such as lower abdominal cramping and painful distended bloating 3-4 days after injection, then received menstrual period 7 days after injection.  Began same menstrual symptoms approximately 13 days later with menstrual period starting again 15 days later.  I?m still menstruating now. Today I am to receive my next vaccination and am concerned I will continue menstruating for the next 3+weeks.
Within a few days of receiving second dose of Pfizer vaccine, I started noticing an odd, unpleasant taste on my tongue, which then became a salty/sour taste in my mouth.  My tongue turned white by May and stayed that way.  The bad taste also would not go away.  The roof of my mouth developed a rough spot.  I started waking up with a very dry mouth.   After seeing my primary care doctor and an otolarynologist, it was determined that I have dry mouth (not producing enough saliva).  It has gotten worse in the last two weeks, leading to loss of appetite, significantly reduced food consumption, and severe insomnia.  Various over the counter remedies for dry mouth offer minimal relief.  I am constantly sipping water and talking a lot less because it is uncomfortable to talk with a dry mouth.  The bad taste and other sensations on my tongue seem to be caused by dry mouth.
Patient c/o feeling lightheaded 5 minutes after administration. BP was normal. Gave cold water. Developed itchy red rash across chest ~8 minutes after administration. This began to fade ~15 minutes after administration, but patient then complained that tongue felt funny & began clearing throat. After consulting with our NP,  Epipen was administered (0.3mg), & 911 called. Transported via ambulance ED. Pt reported tongue feeling better after Epipen.
Patient walked out of the office with her mother after receiving the vaccines. They had stopped at the front desk to ask for a note for school and a clerical staff called to report that the client ''passed out''. When I saw her she was standing, and her mother was holding her tight in a hug. When asked what happened, she said she got dizzy and fell on the floor. She denied hitting her head. Placed her on a chair. She admitted that she did not eat any breakfast. The mother stated that she was planning to treat her to a breakfast at a restaurant after getting the shots. A pouch of juice was given. No other problem noted. The client verbalized feeling better and got up, went out via the elevator with a steady gait.
low temperature(96.6) headache, chills, body aches, extreme nausea and diarrhea itching pain at injection site swollen painful armpit. Still not able to eat as of 12-20  have lost 10 lbs and weak still swollen under the arm.
Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021; Vaccine received past its 30 days Expiry date; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine received past its 30 days Expiry date) and PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Feb-2022 at 2:20 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 11-Feb-2022 at 2:20 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine received past its 30 days Expiry date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine received past its 30 days Expiry date) and PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient census ethnicity reported.  Concomitant medication of the patient was not reported.  On 11-Feb-2022 patient received Moderna booster dose.  Vaccine administration time was given as 11-Feb-2022 at 14:20:53.  No treatment information was provided by the reporter.   This case was linked to MOD-2022-542869 (Patient Link).
No adverse effects reported.; an unspecified number of patients received improperly stored dose of RECOMBIVAX, GARDASIL 9, MMRII, or PROQUAD; The report was first received from a practice manager on 07-SEP-2018, and it was recognized as non-valid because report did not obtain any patient identify.  Follow-up information has been received from the practice manager on 18-SEP-2018.  This spontaneous report refers to a patient of unknown age and gender. Information of concurrent condition, medical history and concomitant therapy was not provided.       On 02-JUL-2018, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (recombinant Human albumin) (strength and route were unknown) (lot#  N024562 and expiration date 06-MAR-2019) for prophylaxis (Incorrect product storage). The sterile diluent (MERCK STERILE DILUENT) was properly stored. No adverse event was reported.  The excursion temperature on 22-SEP-2017, 17-OCT-2017, 06-DEC-2017, 07-DEC-2017, 30-JAN-2018, 23-FEB-2018, 18-MAY-2018, 05-JUL-2018, 15-AUG-2018 was 6 degree Celsius for maximize 8.75 hours. The excursion temperature on 02-MAR-2018, 27-AUG-2018 was 7 degree Celsius for maximize 8.75 hours. The excursion temperature on 07-DEC-2017 was 8 degree Celsius for maximize 15 hours. The call was not because of data logger.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1809USA003709: US-009507513-1810USA001951: US-009507513-1810USA001952: US-009507513-1810USA001953: US-009507513-1810USA001954: US-009507513-1810USA001955: US-009507513-1810USA001956: US-009507513-1810USA001957: US-009507513-1810USA001959:
Right deltoid 2 1/2 cm induration, 6 x 6 cm redness. Apply cold compress to right arm
itching at injection site; warm at injection site; This spontaneous case was reported by a consumer and describes the occurrence of   in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015M20A) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
pt stated that about 2 days after he took the covid vax he started getting vertigo symptoms.  He said whether if he was standing up or laying down he was dizzy.  He called his PCP and he was referred to an ENT Dr.  The ENT scoped his throat, the inner ear and nose. He found everything to be normal.  He will forward his results to PCP and he has an appt. on 3/4/2021.  Pt had these symptoms about 4 weeks.